The Fast Track designation de-risks the anal cancer program and provides rolling review and Priority Review eligibility. Monitor for initiation of a pivotal study, partnership announcements, and upcoming data readouts. The stock may react positively near-term but long-term value depends on clinical execution.
Drug in focus
ONCY drug pipeline →pelareorep
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2/3
- Time to market
- At least 3-5 years (Phase 3 just launching; no BLA/NDA filed)
- Next catalyst
- None dated
What to watchOncolytics is a single-asset clinical-stage biotech with no approved products. The stock trades at ~$0.92 against a mean analyst price target of ~$4.94 (~5x upside), but the company has limited cash (~$12.4M as of Q3 2025) and has tapped a $75M ATM facility, significant dilution risk. Watch for the Phase 3 pancreatic cancer trial launch (H1 2026) and any anal cancer registration updates, but do not expect a near-term binary catalyst.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 20 $0.8500entry
- T+1 · 4mo ago +1.00%α +0.17% · $0.8585
- T+5 · 4mo ago −4.45%α −4.02% · $0.8122
- T+20 · 3mo ago −3.21%α −7.33% · $0.8227
- T+60 · 5w ago −42.35%α −47.19% · $0.4900
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oncolytics Biotech announced FDA Fast Track Designation for pelareorep in combination with a checkpoint inhibitor for second-line and later anal cancer (SCAC). This is the third Fast Track designation in gastrointestinal cancers, supporting a registrational pathway in an indication with no FDA-approved therapies and an estimated $1 billion U.S. market opportunity.
Key Facts
- FDA granted Fast Track Designation for pelareorep + checkpoint inhibitor in inoperable, locally recurrent or metastatic SCAC after prior systemic therapy.
- Third Fast Track designation in GI cancers (colorectal, pancreatic, anal).
- GOBLET study data: ORR ~30%, median DOR ~15.5 months, 12-month OS 82% vs 45.7% historical.
- No FDA-approved therapies exist for patients progressing after first-line standard of care in SCAC.
- Company believes it has a clear regulatory framework for a pivotal study following April 2026 FDA meeting.
Financial Impact
Estimated U.S. commercial opportunity approaching $1 billion annually per company press release; no company-reported financial figures in filing.
Risk Factors
- Clinical trial risk: pivotal study may fail to meet endpoints.
- Financing risk: clinical-stage company may need to raise capital to fund development.
- Competitive risk: other therapies may emerge for SCAC.
- Regulatory risk: Fast Track does not guarantee approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000045 |
| Document: oncolyticsscacfasttrack.htm | 0001129928-26-000045 |
| Document: 0001129928-26-000045-index-headers.html | 0001129928-26-000045 |
| Document: 0001129928-26-000045-index.html | 0001129928-26-000045 |
| Document: 0001129928-26-000045.txt | 0001129928-26-000045 |
Track record
32 reports on ONCY
3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +10.53% at T+5 after the Apr 6, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 3/10 Entry $0.3700 Now $0.3400 −8.11% settles Dec 14
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 3/10 Entry $0.3720 Now $0.3400 −8.60% settles Dec 11
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 3/10 Entry $0.4077 Now $0.3400 −16.61% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 4/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $0.4248 Now $0.3400 −19.96% settles Dec 3
- Oct 27, 202620d ago 8-K Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 27, 202620d ago Press Release Bullish 6/10 Entry $0.4623 Now $0.3400 −26.45% settles Nov 24
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.4986 Now $0.3400 −31.81% settles Nov 17
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers